(CHD) Church & Dwight - Overview
Stock: Baking Soda, Laundry Detergent, Toothbrush, Pregnancy Test, Condom
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.26% |
| Yield on Cost 5y | 1.92% |
| Yield CAGR 5y | 3.91% |
| Payout Consistency | 92.1% |
| Payout Ratio | 27.5% |
| Risk 5d forecast | |
|---|---|
| Volatility | 18.5% |
| Relative Tail Risk | 0.88% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.22 |
| Alpha | -9.56 |
| Character TTM | |
|---|---|
| Beta | 0.037 |
| Beta Downside | 0.052 |
| Drawdowns 3y | |
|---|---|
| Max DD | 27.28% |
| CAGR/Max DD | 0.29 |
Description: CHD Church & Dwight December 19, 2025
Church & Dwight Co. (NYSE: CHD) is a diversified consumer-goods company that develops, manufactures, and markets a broad portfolio of household, personal-care, and specialty products across three segments: Consumer Domestic, Consumer International, and Specialty Products. Its flagship brands include ARM & HAMMER (baking-soda-based cleaners, cat litter, and feed additives), TROJAN (condoms and lubricants), OXICLEAN (stain-removers and bleach alternatives), SPINBRUSH (toothbrushes), FIRST RESPONSE (pregnancy/ovulation tests), NAIR (depilatories), and a suite of niche offerings such as WATERPIK (water flossers) and ZICAM (cold-relief medicines).
In FY 2023 the company reported net sales of roughly **$5.3 billion**, an adjusted earnings-per-share of **$2.15**, and an operating margin of **≈13 %**. CHD paid a quarterly dividend of **$0.45**, yielding about **3.2 %** on its current price, and has raised the dividend for 15 consecutive years, underscoring its cash-flow stability.
Key drivers of CHD’s performance include: (1) **Consumer-staples resilience** – even in a tightening economy, demand for cleaning and personal-care essentials remains relatively inelastic; (2) **Input-cost volatility** – prices for soda ash, surfactants, and other chemicals can compress margins, making the firm’s long-term supply contracts a material risk factor; and (3) **E-commerce penetration** – online sales now account for roughly **12 %** of total revenue, accelerating growth in higher-margin private-label and direct-to-consumer channels.
For a deeper, data-driven look at CHD’s valuation metrics and scenario analysis, you may find the research tools on ValueRay useful.
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 736.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 1.65 > 1.0 |
| NWC/Revenue: 1.55% < 20% (prev 15.14%; Δ -13.60% < -1%) |
| CFO/TA 0.13 > 3% & CFO 1.14b > Net Income 736.8m |
| Net Debt (1.80b) to EBITDA (1.31b): 1.37 < 3 |
| Current Ratio: 1.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (239.6m) vs 12m ago -3.19% < -2% |
| Gross Margin: 44.73% > 18% (prev 0.46%; Δ 4427 % > 0.5%) |
| Asset Turnover: 69.72% > 50% (prev 68.75%; Δ 0.97% > 0%) |
| Interest Coverage Ratio: 9.21 > 6 (EBITDA TTM 1.31b / Interest Expense TTM 93.6m) |
Altman Z'' 3.17
| A: 0.01 (Total Current Assets 1.60b - Total Current Liabilities 1.50b) / Total Assets 8.91b |
| B: 0.75 (Retained Earnings 6.70b / Total Assets 8.91b) |
| C: 0.10 (EBIT TTM 862.4m / Avg Total Assets 8.90b) |
| D: 0.0 (Book Value of Equity 0.0 / Total Liabilities 4.92b) |
| Altman-Z'' Score: 3.17 = A |
Beneish M -2.99
| DSRI: 0.97 (Receivables 593.4m/600.8m, Revenue 6.20b/6.11b) |
| GMI: 1.02 (GM 44.73% / 45.69%) |
| AQI: 1.13 (AQ_t 0.73 / AQ_t-1 0.64) |
| SGI: 1.02 (Revenue 6.20b / 6.11b) |
| TATA: -0.05 (NI 736.8m - CFO 1.14b) / TA 8.91b) |
| Beneish M-Score: -2.99 (Cap -4..+1) = A |
What is the price of CHD shares?
Over the past week, the price has changed by +4.45%, over one month by +17.55%, over three months by +17.02% and over the past year by -3.41%.
Is CHD a buy, sell or hold?
- StrongBuy: 7
- Buy: 2
- Hold: 10
- Sell: 4
- StrongSell: 1
What are the forecasts/targets for the CHD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 96.1 | -4.5% |
| Analysts Target Price | 96.1 | -4.5% |
| ValueRay Target Price | 105.1 | 4.6% |
CHD Fundamental Data Overview January 31, 2026
P/E Forward = 24.3902
P/S = 3.648
P/B = 5.2291
P/EG = 2.1211
Revenue TTM = 6.20b USD
EBIT TTM = 862.4m USD
EBITDA TTM = 1.31b USD
Long Term Debt = 2.20b USD (from longTermDebt, two quarters ago)
Short Term Debt = 28.9m USD (from shortTermDebt, two quarters ago)
Debt = 2.21b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.80b USD (from netDebt column, last quarter)
Enterprise Value = 24.20b USD (22.40b + Debt 2.21b - CCE 409.0m)
Interest Coverage Ratio = 9.21 (Ebit TTM 862.4m / Interest Expense TTM 93.6m)
EV/FCF = 23.67x (Enterprise Value 24.20b / FCF TTM 1.02b)
FCF Yield = 4.23% (FCF TTM 1.02b / Enterprise Value 24.20b)
FCF Margin = 16.48% (FCF TTM 1.02b / Revenue TTM 6.20b)
Net Margin = 11.88% (Net Income TTM 736.8m / Revenue TTM 6.20b)
Gross Margin = 44.73% ((Revenue TTM 6.20b - Cost of Revenue TTM 3.43b) / Revenue TTM)
Gross Margin QoQ = 45.85% (prev 45.06%)
Tobins Q-Ratio = 2.72 (Enterprise Value 24.20b / Total Assets 8.91b)
Interest Expense / Debt = 2.12% (Interest Expense 46.8m / Debt 2.21b)
Taxrate = 23.71% (44.6m / 188.1m)
NOPAT = 657.9m (EBIT 862.4m * (1 - 23.71%))
Current Ratio = 1.06 (Total Current Assets 1.60b / Total Current Liabilities 1.50b)
Debt / Equity = 0.52 (Debt 2.21b / totalStockholderEquity, two quarters ago 4.22b)
Debt / EBITDA = 1.37 (Net Debt 1.80b / EBITDA 1.31b)
Debt / FCF = 1.76 (Net Debt 1.80b / FCF TTM 1.02b)
Total Stockholder Equity = 4.38b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.28% (Net Income 736.8m / Total Assets 8.91b)
RoE = 16.81% (Net Income TTM 736.8m / Total Stockholder Equity 4.38b)
RoCE = 13.09% (EBIT 862.4m / Capital Employed (Equity 4.38b + L.T.Debt 2.20b))
RoIC = 9.98% (NOPAT 657.9m / Invested Capital 6.59b)
WACC = 5.65% (E(22.40b)/V(24.61b) * Re(6.05%) + D(2.21b)/V(24.61b) * Rd(2.12%) * (1-Tc(0.24)))
Discount Rate = 6.05% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -1.51%
[DCF Debug] Terminal Value 87.08% ; FCFF base≈962.4m ; Y1≈1.04b ; Y5≈1.29b
Fair Price DCF = 151.2 (EV 38.10b - Net Debt 1.80b = Equity 36.31b / Shares 240.1m; r=5.90% [WACC]; 5y FCF grow 9.21% → 2.90% )
EPS Correlation: 37.07 | EPS CAGR: 0.95% | SUE: 0.66 | # QB: 0
Revenue Correlation: 89.06 | Revenue CAGR: 6.53% | SUE: 0.30 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.96 | Chg30d=-0.001 | Revisions Net=-4 | Analysts=13
EPS current Year (2026-12-31): EPS=3.72 | Chg30d=-0.007 | Revisions Net=-1 | Growth EPS=+5.5% | Growth Revenue=+2.8%
EPS next Year (2027-12-31): EPS=3.97 | Chg30d=+0.003 | Revisions Net=+1 | Growth EPS=+6.7% | Growth Revenue=+3.3%